In estrogen-dependent breast cancer cells, PLAC1 expression was downregulated by antiestrogen treatment [15, 16] further suggesting that it may be a useful biomarker to follow treatment responsiveness and resistance in patients with hormone-dependent tumors. This evidence concerns the gene PLAC1 and breast cancer.